In vascular smooth muscle, calcium overload is linked to advancing age. The pharmacokinetics of Sulfanilamide (SA), a compound with antibacterial properties, was evaluated in a preclinical model of vascular calcification. SA was used since it is useful to study possible modifications in the renal and hepatic management of drugs. 
| INTRODUCTION
The process of natural ageing of human arteries is reflected in a marked increase in the calcium content. As the age advances, human blood vessels produce a calcium accumulation 5-to 100-fold higher than the respective infantile arteries. 1, 2 This is a continuous development process that begins many years before cytotoxic levels of calcium overload are reached. In vascular smooth muscle, calcium overload is a highly pathogenic event that finally leads to calcification and necrotization of the arterial wall. Attempts have been made to study this process and their consequences using available animal models. In these experimental models the vascular overload of calcium associated with advancing age is less pronounced than in humans.
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Calcium overload with simultaneous structural damage of the arterial walls can be achieved by administration of high doses of vitamin D 3 to young adult rats. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Under these conditions calcium overload occurs in a few days. In vascular ageing and different vascular human pathologies such as arteriosclerosis, calcium is fixed in the elastic fibres and makes the vessel more rigid. Vitamin D 3 could accelerate this process in young animals by increasing extracellular calcium levels, modifying the molecular structure of elastic fibres and promoting the synthesis of intermediate proteins that bind calcium ions to elastic fibres. 4 In this experimental model, calcium overload is not limited to the arterial wall and has been observed in many organs such as the kidneys or the heart, which leads to the impairment of the function of the respective organ. [5] [6] [7] [8] [9] [10] [11] [12] It is important to mention that the administration of a single high dose of vitamin D3 to young adult rats is essential to obtain the vascular overload of calcium associated with advancing age in animals.
As vitamin D3 has a half-life time between 5 and 8 hours, 13 10 days after its single administration the preclinical model of vascular calcification will be obtained but vitamin D3 level will not be at high levels.
The preserved function of organs, such as the kidneys or liver, is an important determinant of the pharmacokinetics of drugs. [14] [15] [16] It is known that impairment of renal function leads to modifications in the renal elimination of drugs mediated by different mechanisms. [14] [15] [16] On the other hand, there is a clear interrelationship between the excretory functions of the kidney and liver, so that the damage to one system could be compensated for by the other. [16] [17] [18] [19] The integrity of the vascular system is also necessary for a good function of the organs and, consequently, for an adequate management of drugs. Thus, it is possible that injury to the vascular system will allow changes on the pharmacokinetics of drugs.
Although calcium overload is a common event, which progresses with advancing age, there are few reports on drug pharmacokinetics in this experimental model.
The term Sulfonamide (SA) is used as the generic name for derivatives of para-aminobenzenesulfonamide. 20 In the present study this compound, SA, a model compound of sulfonamide group, was used.
This is a well known drug, acetylated by the liver and preferentially excreted by the kidneys. SA is a good model to study possible modifications in the renal and hepatic handling of drugs.
We have previously evaluated the pharmacokinetics of SA in a rat model of early arterial calcinosis obtained by a single high dose of vitamin D 3 5 days before the experiment. The results have shown an increase in total body clearance of this drug, probably associated with modifications in its metabolism and/or in organ extraction. Since renal and vascular system integrity is required for proper drug management, we propose to evaluate the pharmacokinetic parameters of SA and additional parameters that could determine possible modifications of the pharmacokinetics of this drug in rats with sustained vascular calcification induced by administration of a single high dose of vitamin D 3 10 days before the experiments.
| RESULTS
The treatment with vitamin D 3 resulted in a large increase in the calcium content of the aortic tissue and an increase in systolic arterial pressure. Plasma calcium levels did not show differences between the two groups studied (Table 1) . Figure 1A shows the mean plasma concentration-time profiles for SA in control and vitamin D 3 -treated rats. The following equation was used to describe the bi-exponential concentration-time curves for SA: 
| Pharmacokinetic study
C = A e −αt + B e −βt
P<.05
where C is the SA concentration at time t after SA administration, α and β are the rate constants for the distribution and elimination phases, re- Table 2 shows the pharmacokinetic parameters of SA. An increase in the systemic clearance of SA ( Figure 1B ) and a decrease in the elimination rate microconstant from the central compartment ( Figure 1C) were observed in treated rats.
The total compartment volume did not change with the treatment;
however there was an increase in the volume of the central compartment and a decrease in the volume of the peripheral compartment in animals with vascular calcification (Table 2 ). Figure 2A shows concentration-time profiles for acetylatedSulfanilamide (ASA) in both experimental groups. In order to evaluate the plasma concentration-time curves for ASA, the following equation
where C is the ASA concentration at time t after SA administration, k is the appearance rate constant of ASA, and A represents the maximum (extrapolated) ASA plasma level.
A statistically significant increase in the plasma appearance rate constant of ASA was observed in the treated group ( Figure 2B ).
In order to clarify these findings, it was decided to evaluate the content of SA and ASA in liver and kidney homogenates.
| Determination of SA and ASA levels in renal and hepatic homogenates
The content of SA in liver homogenates was significantly lower in rats treated with vitamin D 3 ( Figure 3A ). In contrast, hepatic ASA content was increased in the same experimental group ( Figure 3B ). Figure 3C ). The acetylated drug content was not significantly different between control and treated rats ( Figure 3D ).
The liver is the main organ of drug metabolism. It is known that this ability depends on the enzymatic systems and the hepatic blood flow.
Thus, we decided to study the hepatic arterial blood flow. As SA is acetylated we also evaluated the activity of N-acetyltransferase. These studies were also performed in the kidneys because they are the main site of SA excretion. AUC, area under curve; Cl, systemic clearance of Sulfanilamide; K 1-0 , elimination rate microconstant from the central compartment; K 1-2 , K 2-1 rate microconstants of transfer from central to peripheral compartments and peripheral to central compartments respectively; VdT, total volume of distribution; VdC, volume of the central compartment; VdP, volume of the peripheral compartment t 1/2 (β), elimination half-life; A, B, the initial values of the distribution and elimination components, respectively; α, β, the disappearance rates constants for the distribution and elimination components, respectively. *P<.05. 
| Renal and hepatic blood flow determinations
The hepatic arterial blood flow did not show significant differences between control and treated rats ( Figure 4A ). In contrast, renal blood flow was significantly lower in rats with vascular calcification ( Figure 4B ).
| N-acetyltransferase activity assay
N-acetyltransferase activity in liver homogenates was statistically increased in rats treated with vitamin D 3 ( Figure 5A ). On the other hand, there was no difference between both experimental groups in N-acetyltransferase activity in homogenates of kidneys ( Figure 5B ).
| Renal clearance studies
The renal clearance of a drug is often expressed by the concept of a virtual volume of plasma from which the substance is completely eliminated through the kidneys per unit time. The following equation was used to describe the renal clearance (Clr) of SA and ASA:
where C u (mg/mL) is SA or ASA concentration in urine, V (mL/min per 100 g b.w.) is urine flow. Finally, C p (mg/mL) is SA or ASA plasma concentration.
The SA and ASA renal clearance were both significantly lower in treated rats ( Figure 6A ,B). The study of calcium level in the renal arteries was performed in order to explain, at least in part, some of these results. A significant increase in calcium content in the renal arteries was found in rats with arterial calcinosis ( Figure 6C ).
| DISCUSSION
Ageing induces calcium accumulation in the vascular system. The largest increase is seen in compliance vessels, such as the aorta, but marked increases in small muscular arteries also occur. It is clearly a continuous development process that begins many years before the cytotoxic levels of calcium overload are reached. An increase in calcium content of the arterial wall can be produced in young rats by treatment with vitamin D 3 .
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The aim of the present study was to evaluate the pharmacokinetics 
P<.05
The rats with vascular calcification showed a large increase in calcium content in the aorta and, in connection with this, an increase in systolic arterial pressure. In this sense, Atkinson 7 found that intracellular free calcium can accumulate in vascular smooth muscle cells and, therefore, alters the contractile properties of these cells. The results of this study corroborate this preclinical model previously described.
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We have previously shown 8 In this regard, the administration of 1,25-(OH) 2 vitamin D 3 is known to acutely increase the total pressor response in animals infused with catecholamines and may selectively constrict regional circulations.
22
The increased calcium availability within smooth muscle cells would increase arterial resistance. 23 K 1-0 is affected by the variables that determine the elimination of drugs from the central compartment, such as the metabolism, renal and biliary excretion. Thus, the decrease of K 1-0 observed in treated animals indicates a lower elimination of SA, which could be due to a lower metabolism, a lower excretion or both.
The SA is mainly metabolized by acetylation. 24 Interestingly, this study has shown a higher plasma appearance rate constant of ASA in rats with vascular calcification. In addition, the renal and hepatic content of SA and ASA were evaluated in both control and treated groups.
The treated group showed an absolute increase of ASA in hepatic tissue, and there were no variations in renal ASA levels.
N-acetylation is a phase II conjugation reaction mediated by
N-acetyltransferase. As N-acetyltransferase metabolizes SA, we decided to evaluate the N-acetyltransferase activity in hepatic and renal tissues. This enzyme is localized in both the liver and the kidneys. The liver is the main site of drug metabolism, which in turn depends on two factors: the metabolic capacity of the liver and the hepatic blood flow.
14 Treated rats did not show modifications in the hepatic arterial blood flow. The increased activity of N-acetyltransferase in the liver of rats with vascular calcification may explain the increase of ASA content in the liver and the higher plasma appearance rate of ASA. In this regard, it has been reported that calcium modulates N-acetyltransferase activity. 25 Gomez-Cabronero et al. 25 demonstrated that the addition of micromolar levels of calcium to rat spleen microsomes rapidly enhances acetyltransferase activity. This calcium effect was explained by an alteration in the apparent Km of the enzyme for the substrate acetyl-CoA without showing any significant effect in the Vmax of the acetylation reaction. These authors also suggested that calcium modulates acetyltransferase activity by a mechanism that appears to be independent of calmodulin or protein phosphorylation. Moreover, an increase in protein synthesis or a decrease in protein degradation of hepatic N-acetyltransferase in this preclinical model of vascular calcification cannot be discarded.
In this study, renal clearance of SA and ASA were also evaluated.
These parameters were significantly lower in treated rats. It is well 
P<.05
it was also reported that noradrenaline induces higher levels of intracellular calcium. 28 In this regard, we have described damage in renal function and structure linked to vascular calcification. [9] [10] [11] [12] Renal histological studies showed tubular alteration with vacuoles in the cytoplasm and glomeruli of reduced size in rats with vascular calcium overload. 11, 12 Modifications were also observed in the hemodynamic parameters and in the tubular parameters that were associated with changes in the activity of the medullar sodium pump and content of medullar calcium. 10 Quaglia et al. 10 have also described a decrease in the glomerular filtration rate (40%), which could also contribute to decreased renal excretion of SA.
In summary, the decrease observed in the elimination rate microconstant (K 1-0 ) of SA from the central compartment in rats with vascular calcification is due to an important decrease in its renal excretion, which is not completely compensated by the increase in its metabolism.
The elimination of drugs from the body is, fundamentally, a concerted action of the liver and the kidneys. Thus, impaired renal function may be associated with an increase in hepatic activity in rats with vascular calcification. In this regard, the reciprocal compensation of renal and hepatic function, concerning drug elimination, has previously been described in the presence of different pathologies. [16] [17] [18] [19] This study highlights the numerous factors that influence the sys- 
| METHODS

| Experimental animals and treatment
Adult male Wistar rats (320-380 g body weight) were randomly divided into two groups: control and treated rats. Treated rats were injected with a single high dose of vitamin D 3 (300 000 IU/kg b.w., intramuscular) 10 days before the experiment in order to induce a vascular calcium overload as previously described. 
| Experimental procedures
| Measurement of arterial pressure
Systolic arterial pressure was measured in all experimental groups using a Harvard indirect rat tail blood pressure monitor (Harvard Apparatus, Millis, MA, USA) connected to a Harvard student oscillograph.
| Biochemical determinations
Blood samples (obtained by cardiac puncture) from animals of both experimental groups were used for the determination of calcium.
Calcium plasma levels were determined spectrophotometrically with commercial reagent kits (Wiener Laboratory, Rosario, Argentina).
| Tissue calcium analysis
Samples 
| Pharmacokinetic studies
These studies were performed similarly to those described previously. 8, 19, 29 The animals were anaesthetized with sodium thiopental 
| Determination of SA levels in renal and hepatic homogenates
Preparation of renal and hepatic homogenates
At the end of the pharmacokinetic studies, the kidneys and the liver were rapidly removed. Then, the renal and hepatic tissues were cleaned, dried, weighed, and placed in isotonic saline solution.
These tissues were thoroughly homogenized in 250 mmol/L sucrose, 10 mmol/L HEPES-Tris (pH 7.40) for SA and ASA analyses.
Determinations of SA and ASA concentrations in tissues samples were performed as described by Bratton and Marshall. 30 The protein content was determined using the method of Sedmak and Grossberg. 
| Renal clearance studies
These studies were performed as previously described. [9] [10] [11] The renal clearance of SA and ASA were calculated by conventional formulae for each animal.
| Renal and hepatic blood flow determinations
Another set of experimental animals (control and treated rats) was used to evaluate renal and hepatic blood flow as previously described in our laboratory. 8, 19 Orange microspheres, 15 μm in diameter (Molecular Probes, Eugene, OR, USA), were infused as a bolus into the carotid artery (previously catheterized) followed by a washout with 1 mL saline. Arterial reference blood was collected from a catheter inserted in the femoral artery at a rate of 1 mL/min, which was continued for 60 seconds after 
| N-acetyltransferase activity assay
Another set of experimental animals was used to evaluate N-acetyltransferase activity. The kidneys and the liver were rapidly removed; then, renal and hepatic tissues were cleaned, dried, weighed, and placed in isotonic saline solution. These tissues were thoroughly homogenized 30% P/V in 0.05 mol/L phosphate buffer (pH 6.80). Protein content was assayed using the method of Sedmak and Grossberg. 
| Statistical analysis
Statistical analysis was performed using an unpaired t test. When variances were not homogeneous a Welch's correction was employed. P values<.05 were considered significant. Values are expressed as mean±standard error (SE). For these analyses, GraphPad software (GraphPad Software, San Diego, CA, USA) was used. The concentration-time graphics for SA and ASA for each individual animal were fitted with the PKCALC computer program as previously described. 8, 19, 29, 34, 35 The choice of best fit was based on both the determination coefficient values (R
2
) and F-test.
| Reagents
All chemicals were purchased from Sigma chemical (St Louis, MO, USA).
